The University of Texas MD Anderson Cancer Center is launching a science exhibition, showcasing the research, technologies, and new therapies bringing progress in the mission to end cancer.
Researchers at The University of Texas MD Anderson Cancer Center have determined that mutations in the KDM6A gene—common in advanced bladder cancer—may serve as a predictive biomarker to determine which patients are less likely to benefit from standard chemotherapy but may respond better to immunotherapy.
